Frontline Treatment Approaches for Advanced Clear Cell RCC

March 5, 2024

By Elizabeth Plimack, MD
Benjamin L. Maughan, MD, PharmD

Opinion

Video

The panelists summarize their approaches to choosing frontline treatment for advanced clear cell RCC, balancing long-term and short-term efficacy data on IO-IO versus IO-TKI regimens based on recent study results.

EP: 1.Long Term Follow Up Data From Checkmate 214 on Nivolumab Plus Ipilimumab in First Line Clear Cell RCC

EP: 2.Subgroup Analysis from CLEAR Trial: Efficacy Outcomes by Baseline Tumor Size in Treatment of Metastatic Clear Cell RCC

EP: 3.Network Meta-Analysis Comparing Efficacy of Lenvatinib Plus Pembrolizumab to Other First Line Treatments for Metastatic Clear Cell RCC

Now Viewing

EP: 4.Frontline Treatment Approaches for Advanced Clear Cell RCC

EP: 5.Treatment Decisions for Favorable Risk RCC

EP: 6.Managing Immune-Related Toxicities with Frontline RCC Therapies

EP: 7.Treating Patients with RCC and Brain, Liver, or Bone Metastases

EP: 8.Frontline Therapy for Patients With Non-Clear Cell RCC

EP: 9.Non-Clear Cell RCC: Key Learnings and Future Research Directions

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!